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SummAry – The aim of the study was to assess the intensity and distribution of galectin-3 
expression in benign and malignant thyroid neoplasms by immunohistochemical method. Immu-
nohistochemical expression of galectin-3 was analyzed in surgical thyroid specimens from 82 pati-
ents with histopathologic diagnosis of follicular adenoma (n=32), hürthle cell adenoma (n=10) and 
papillary carcinoma (n=40). results of intracytoplasmatic and intranuclear expression of galectin-3 
were scored using a semi-quantitative scale for intensity. Intracytoplasmatic expression of galectin-3 
was positive in 18 (43%) benign neoplasms and in all 40 malignant neoplasms. The accuracy, sensi-
tivity and specificity of intracytoplasmatic expression of galectin-3 as a malignant marker in thyroid 
neoplasms were 78.1%, 100% and 57.1%, respectively. Intracytoplasmatic expression of galectin-3 
was positive in 10 (31%) cases of follicular adenoma and 8 (80%) cases of hürthle cell adenoma. The 
accuracy, sensitivity and specificity of intranuclear expression of galectin-3 as a malignant marker 
in thyroid neoplasms were 84.1%, 100% and 69%, respectively. There was no strong intensity of 
either intracytoplasmatic or intranuclear expression of galectin-3 in benign thyroid neoplasms, and 
no weak intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in malignant 
neoplasms. There was no statistically significant difference between intracytoplasmatic and intra-
nuclear expression of galectin-3 in benign thyroid neoplasms. The results of our study indicate that 
the immunohistochemical expression of galectin-3 is a highly sensitive marker of malignancy, with 
low specificity in differentiating malignant from benign thyroid neoplasms. The analysis of intensity 
and distribution of galectin-3 expression could improve the specificity of the method.
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Introduction
With the advent of the era of molecular pathology, 
some researchers believe that traditional evaluation of 
h&e-stained slides may be at the brink of extinction, 
while others believe that traditional h&e-staining 
still is and will remain the ‘gold standard’ of diag-
nostic pathology1-4. molecules that may be expressed 
during the crucial steps in the development of malig-
nancy are expected to have strong effects on clinical 
management5,6.
Although postsurgical analysis of tumor architec-
ture usually provides the current criteria for definitive 
evidence of malignancy in thyroid neoplasms, distinc-
tion of hyperplastic nodules from papillary carcinoma 
or follicular carcinoma can be difficult. In encapsu-
lated neoplasms composed exclusively of follicles and 
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lacking capsular and vascular invasion, distinction 
between follicular adenoma and follicular variant of 
papillary carcinoma rests on the pathologist’s percep-
tion of nuclear characteristics of follicular cells. fur-
thermore, differentiation between follicular adenoma 
and follicular carcinoma may be difficult in cases of 
minimally invasive follicular carcinoma.
Several molecular markers have been reported 
to be helpful in distinguishing between benign and 
malignant follicular-patterned lesions of the thyroid. 
Among them, the most promising is a beta-galacto-
side-binding protein galectin-37-13. despite its high 
sensitivity, some authors have reported its expression 
in benign thyroid lesions, contributing to its lower 
specificity14-16. 
In the current study, we used the immunohis-
tochemistry method to study the intensity and dis-
tribution of galectin-3 expression in surgical material 
from benign and malignant thyroid neoplasms. Our 
aim was to evaluate the efficiency of galectin-3 ex-
pression as a molecular marker of malignancy.
Patients and Methods
The patients included in this study were assigned 
from university department of ent and head and 
neck Surgery, Sestre milosrdnice university hospital 
Center, Zagreb, Croatia. We analyzed the immuno-
histochemical expression of galectin-3 in surgical thy-
roid specimens from 82 patients with histopathologic 
diagnosis of follicular adenoma (n=32), hürthle cell 
adenoma (n=10) and papillary carcinoma (n=40).
for immunohistochemistry, mouse monoclonal 
antibody to galectin-3 (novocastra, uK; 1:100) was 
prepared according to the manufacturer’s instruc-
tions. Immunohistochemistry was performed using 
the indirect avidin-biotin complex immunoperoxidase 
method.
results of intracytoplasmatic and intranuclear ex-
pression of galectin-3 were scored using a semi quan-
titative scale for intensity: negative (-), weak (+), mod-
erate (++), or strong (+++).
Sensitivity, specificity, predictive value, and diag-
nostic accuracy were assessed to evaluate the efficiency 
of galectin-3 as a malignant marker in thyroid neo-
plasms.
data analysis was performed using statistical χ2-
test or fisher exact test.
Results
Intracytoplasmatic expression of galectin-3
Intracytoplasmatic expression of galectin-3 was 
positive in 18 (43%) benign neoplasms and in all 40 
malignant neoplasms (100%) (fig. 1). There was a 
statistically significant difference in the intracytoplas-
matic expression of galectin-3 between benign and 
malignant thyroid neoplasms (p<0.01) (table 1).
The accuracy, sensitivity and specificity of intra-
cytoplasmatic expression of galectin-3 as a malignant 
marker in thyroid neoplasms were 78.1%, 100% and 
57.1%, respectively. Positive and negative predictive 
values were 68.9% and 100%, respectively.
Intracytoplasmatic expression of galectin-3 was 
positive in 10 (31%) cases of follicular adenoma and 8 
(80%) cases of hürthle cell adenoma. There was a sta-
tistically significant difference in intracytoplasmatic 
expression of galectin-3 between follicular adenoma 
and hürthle cell adenoma (p<0.01) (table 2).
Figure 1. Strong intensity of intracytoplasmatic 
and intranuclear expression of galectin-3 in thyroid 
papillary carcinoma (H&E)
Table 1. Intracytoplasmatic expression of galectin-3 in 





benign neoplasms 18 24 42
malignant neoplasms 40 0 40
fisher exact test: p<0.01
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There was a statistically significant difference in 
intracytoplasmatic expression of galectin-3 in papil-
lary carcinoma vs. follicular adenoma (fisher exact 
test: p<0.01), and in papillary carcinoma vs. hürthle 
cell adenoma (fisher exact test: p<0.05).
Intranuclear expression of galectin-3
Intranuclear expression of galectin-3 was positive 
in 13 (31%) benign neoplasms and in all 40 malignant 
neoplasms (100%). There was a statistically significant 
difference in intranuclear expression of galectin-3 
between benign and malignant thyroid neoplasms 
(p<0.01) (table 3). The accuracy, sensitivity and speci-
ficity of intranuclear expression of galectin-3 as a 
malignant marker in thyroid neoplasms were 84.1%, 
100% and 69%, respectively. Positive and negative 
predictive values were 75.5% and 100%, respectively.
Intranuclear expression of galectin-3 was positive 
in 7 (22%) cases of follicular adenoma and 6 (60%) 
cases of hürthle cell adenoma. There was a statisti-
cally significant difference in intranuclear expression 
of galectin-3 between follicular adenoma and hürthle 
cell adenoma (p<0.05) (table 4).
Intensity of intracytoplasmatic and intranuclear 
expression of galectin-3
In 82 patients, the intensity of intracytoplasmatic 
and intranuclear expression of galectin-3 was ana-
lyzed separately. There was no strong intensity of ei-
ther intracytoplasmatic or intranuclear expression of 
galectin-3 in benign thyroid neoplasms, and no weak 
intensity of either intracytoplasmatic or intranuclear 
expression of galectin-3 in malignant neoplasms. 
There was a statistically significant difference in the 
intensity of expression of galectin-3 between benign 
and malignant thyroid neoplasms (p<0.01) (tables 5 
and 6).
Intracytoplasmatic vs. intranuclear expression of 
galectin-3
Intracytoplasmatic and intranuclear expression of 
galectin-3 was present in all malignant thyroid neo-
plasms. Intracytoplasmatic expression of galectin-3 
was positive in 18 benign thyroid neoplasms, and 
intranuclear expression of galectin-3 was positive in 
13 (72%) of these cases too. There were no cases of 
only intranuclear expression of galectin-3. We found 
Table 2. Intracytoplasmatic expression of galectin-3 in 





follicular adenoma 10 22 32
hürthle cell adenoma 8 2 10
fisher exact test: p<0.01
Table 3. Intranuclear expression of galectin-3 in benign 





benign neoplasms 13 29 42
malignant neoplasms 40 0 40
fisher exact test: p<0.01
Table 4. Intranuclear expression of galectin-3 in follicular 





follicular adenoma 7 25 32
hürthle cell adenoma 6 4 10
fisher exact test: p<0.05
able 5. Intensity of intracytoplasmatic expression of galec-
tin-3 in benign and malignant thyroid neoplasms
gal-3 + gal-3 ++ gal-3 +++ gal-3 - total
benign neoplasms 9 9 0 24 42
malignant neoplasms 0 7 33 0 40
χ2-test: p<0.01
Table 6. Intensity of intranuclear expression of galectin-3 
in benign and malignant thyroid neoplasms
gal-3 + gal-3 ++ gal-3 +++ gal-3 - total
benign neoplasms 6 7 0 29 42
malignant neoplasms 0 7 33 0 40
χ 2-test: p<0.01
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no statistically significant difference in intracytoplas-
matic vs. intranuclear expression of galectin-3 in be-
nign thyroid neoplasms (fisher exact test: p=0.8180), 
follicular adenomas (fisher exact test: p=0.3204) and 
hürthle cell adenomas (fisher exact test: p=0.2380).
Discussion
In this study, all malignant thyroid neoplasms 
were found to express galectin-3; however, a substan-
tial number (43%) of benign thyroid neoplasms also 
expressed galectin-3. A few studies have reported 
negative galectin-3 expression in all benign thyroid 
lesions and high galectin-3 expression in common 
malignant thyroid neoplasms7-9,17. later studies pro-
duced conflicting results5,10,14-16. The conflicting results 
reported by various authors may be because they chose 
to accept different thresholds of galectin-3 immunos-
taining as true positive staining, or used different 
galectin-3 antibodies. besides, the interpretation of 
immunohistochemical staining is very subjective and 
can be technically difficult. Coli et al.18 and martins 
et al.14 found immunohistochemical expression of ga-
lectin-3 in 63% and in 45% of follicular adenomas, re-
spectively. maruta et al. found positive immunostain-
ing of galectin-3 in 25% of follicular adenoma fnA 
samples19. In our study, we found intracytoplasmatic 
and intranuclear immunohistochemical expression of 
galectin-3 in 31% and 22% of follicular adenomas, re-
spectively.
niedziela et al. found hürthle cells present in 6 
of 10 galectin-3 positive aspirates, of which 5 lesions 
were benign15. mateša et al. found a statistically sig-
nificant relationship between the presence of hürthle 
cells and positive expression of galectin-3 in hashim-
oto thyroiditis aspirates and a tendency of such a 
relationship in nodular goiter aspirates analyzed by 
rt-PCr method16. In this study, intracytoplasmatic 
and intranuclear immunohistochemical expression 
of galectin-3 was found in 80% and 60% of hürthle 
cell adenomas, respectively. We found a statistically 
significant difference in the expression of galectin-3 
between follicular adenomas and hürthle cell ad-
enomas.
martins et al. found strong galectin-3 immunos-
taining in half of papillary carcinomas, and no weak 
or negative staining in this group. They also found 
strong galectin-3 immunostaining in only 2 (6%) of 31 
follicular adenomas14. hermann et al. found strong ga-
lectin-3 immunostaining in the majority of malignant 
lesions, and only focal reactivity in a few benign ad-
enomatous lesions5. In our study, there was no strong 
intensity of either intracytoplasmatic or intranuclear 
expression of galectin-3 in benign thyroid neoplasms, 
and no weak or negative expression, intracytoplas-
matic or intranuclear, of galectin-3 in malignant neo-
plasms.
Immunohistochemical analysis revealed galectin-3 
to be distributed predominantly in the cytoplasm with 
occasional nuclear localization9,20. mills et al. found 
positive, both intracytoplasmatic and intranuclear, ga-
lectin-3 immunostaining in the cytoblocks of papillary 
carcinoma21. In our study, we found both intracyto-
plasmatic and intranuclear expression of galectin-3 in 
all malignant thyroid neoplasms. Intracytoplasmatic 
expression of galectin-3 was more often present in be-
nign thyroid neoplasms than intranuclear expression 
of galectin-3, but the difference was not statistically 
significant. There were no cases of only intranuclear 
expression of galectin-3.
In conclusion, the results of our study indicate that 
the immunohistochemical expression of galectin-3 
is a highly sensitive marker of malignancy, with low 
specificity in differentiating malignant from benign 
thyroid neoplasms. The analysis of intensity and dis-
tribution of galectin-3 expression could improve the 
specificity of the method.
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Sažetak
IntenZItet I rASPOdJelA ImunOhIStOKemIJSKe eKSPreSIJe GAleKtInA-3 KOd 
nOVOtVOrInA štItnJAČe
D. Mateša-Anić, S. Moslavac, N. Mateša, H. Čupić i Z. Kusić
Cilj istraživanja bio je imunohistokemijskom metodom utvrditi intenzitet i raspodjelu ekspresije galektina-3 u mali-
gnim i benignim tumorima štitnjače. Analizirana je imunohistokemijska ekspresija galektina-3 u kirurškim materijalima 
82 bolesnika od kojih je 32 imalo histopatološku dijagnozu folikularnog adenoma, 10 adenoma hürthleovih stanica i 40 
papilarnog karcinoma. Intenzitet intracitoplazmatske i intranuklearne ekspresije galektina-3 određivan je semikvantitativ-
no. Intracitoplazmatska ekspresija galektina-3 bila je pozitivna u 18 (43%) benignih tumora i kod svih 40 malignih tumora. 
Pouzdanost, osjetljivost i specifičnost intracitoplazmatske ekspresije galektina-3 kao biljega malignosti bile su 78,1%, 
100% i 57,1%. Intracitoplazmatska ekspresija galektina-3 bila je pozitivna u 10 (31%) folikularnih adenoma i u 8 (80%) 
adenoma hürthleovih stanica. Pouzdanost, osjetljivost i specifičnost intranuklearne ekspresije galektina-3 kao biljega ma-
lignosti bile su 84,1%, 100% i 69%. nije bilo jakog intenziteta ekspresije, bilo intracitoplazmatske ili intranuklearne, galek-
tina-3 kod benignih tumora štitnjače, niti je bilo slabog intenziteta ekspresije, bilo intracitoplazmatske ili intranuklearne, 
galektina-3 kod malignih tumora. nije nađena statistički značajna razlika između intracitoplazmatske i intranuklearne 
ekspresije galektina-3 kod benignih tumora štitnjače. Istraživanje je pokazalo da je imunohistokemijska ekspresija galek-
tina-3 visoko osjetljiva kao biljeg malignosti, ali s niskom specifičnošću u odnosu na benigne tumore štitnjače. Analiza 
intenziteta i raspodjele ekspresije galektina-3 može poboljšati specifičnost ove metode.
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